Global Plasma Fractionation Market: Limited reimbursements and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

Published Date: 11/05/2021

The plasma fractionation market is projected to reach USD 43.86 billion by 2027 from USD 28.6 billion in 2020, at a CAGR of 4.3 % during the forecast period. The plasma fractionation market is largely driven by the growing use of immunoglobulin’s in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin.

However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period. Plasma is a blood component, derived from whole blood by plasmapheresis, and used for various therapeutic and medical applications. Human plasma is a source of numerous different proteins, however only few of these proteins are useful for producing therapeutic plasma products. The process of separation, extraction and purification of these proteins from the plasma is called as fractionation process. The proteins extracted from the plasma are mainly categorized into three main classes: immunoglobulin’s which are useful in treatment of autoimmune diseases and increasing the immune response, clotting factors which are used in treatment of blood disorders such as hemophilia and lastly the albumins which are useful in cases of depleted albumin levels or during fluid loss. Plasma fractionation process is mainly based upon different criteria such as solubility of the products, and their physical and chemical conditions such as pH levels, ionic strengths, and temperature, etc. The derived plasma products, also known as Fresh Frozen Plasma (FFP) are then subjected to various mechanical and physical treatments for virus inactivation such as Nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultra filtration and sterile filtration in order to achieve homogeneity of plasma derived from numerous donors and reduce the risks of viral transmissions.

The global market for plasma fractionation is expected to be driven by increasing incidences of blood and immune disorders owing to increasing aging population, along with increasing off-label usage of critical plasma products such as albumins, and immunoglobulin’s. According to Centers of Disease Control (CDC), in 2012 chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease. Improved diagnostic facilities, and ease of access to healthcare along with increasing incidences and prevalence of chronic diseases around the world, are some factors responsible for the rising demand for plasma derived products and is expected to drive the plasma fractionation market during the forecast period of 2016-2024. However, escalating costs of plasma derivatives and the risk factors associated with them, combined with increasing usage of recombinant proteins and products acting as a substitute for the plasma products are expected to restrain the growth of the global plasma fractionation market during the forecast period

Major players in the global plasma fractionation industry include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China). Geographic expansions and collaborations are the key strategies undertaken by these companies to maintain their positions in the market.

Geographically, the plasma fractionation market has been studied for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the plasma fractionation market during the forecast period. Growth in North America is primarily driven by the growing use of immunoglobulin in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD. Furthermore, several innovations in manufacturing processes (e.g. improvement of yield), product developments (e.g. such as subcutaneous IG, IVIg 10% concentration, and IVIg liquid presentation), presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA are also supporting the growth of the plasma fractionation market in these regions.